血液学の最新論文 | Hematopaseo

血液専門医と医療関係者のための情報サイト「ヘマトパセオ」

血液学の最新論文（2018年9月リリース分）New reports on Hematology

Leukemia

Blood Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. 132(13):1452-1454 Russell N, Burnett A, Hills R, Betteridge S, Dennis M, Jovanovic J, Dillon R, Grimwade D; NCRI AML Working Group
Blood Targeted therapy for fusion-driven high-risk acute leukemia. 132(12):1241-1247 Pikman Y, Stegmaier K
Blood A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. 132(11):1125-1133 Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS
Blood Hairy cell leukemia in a child?! 132(11):1216 Bosma M, Bartels M
Blood BCL-2 inhibition in AML: an unexpected bonus? 132(10):1007-1012 Konopleva M, Letai A
Blood Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. 132(10):1039-1049 Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, Mantel R, Smith L, Johnson AJ, Young WB, Johnson AR, Liu L, Byrd JC, Woyach JA
Blood Multiple subperiosteal bone resorption in adult T-cell leukemia/lymphoma. 132(10):1086 Katsuragi T, Tsukada J
Br J Haematol Will Rogers: actor, humourist … and ALL epidemiologist? 182(6):755 Hills R
Br J Haematol Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. 182(6):777-788 Cross NCP, White HE, Evans PAS, Hancock J, Copland M, Milojkovic D, Mason J, Craine S, Mead AJ
Br J Haematol Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. 182(6):830-842 Stosch JM, Heumüller A, Niemöller C, Bleul S, Rothenberg-Thurley M, Riba J, Renz N, Szarc Vel Szic K, Pfeifer D, Follo M, Pahl HL, Zimmermann S, Duyster J, Wehrle J, Lübbert M, Metzeler KH, Claus R, Becker H
Br J Haematol Long-term survival after childhood acute lymphoblastic leukaemia: population-based trends in cure and relapse by clinical characteristics. 182(6):851-858 Smith L, Glaser AW, Kinsey SE, Greenwood DC, Chilton L, Moorman AV, Feltbower RG
Br J Haematol The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. 182(5):654-669 Crassini K, Shen Y, O'Dwyer M, O'Neill M, Christopherson R, Mulligan S, Best OG
Br J Haematol Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. 182(5):693-700 Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM, Yu L, Huang XJ
Br J Haematol The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols. 182(5):705-711 Paganin M, Grillo MF, Silvestri D, Scapinello G, Buldini B, Cazzaniga G, Biondi A, Valsecchi MG, Conter V, Te Kronnie G, Basso G
Haematologica Targeting dihydroorotate dehydrogenase in acute myeloid leukemia. 103(9):1415-1417 Zeng Z, Konopleva M
Haematologica Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia. 103(9):1462-1471 Geyh S, Rodríguez-Paredes M, Jäger P, Koch A, Bormann F, Gutekunst J, Zilkens C, Germing U, Kobbe G, Lyko F, Haas R, Schroeder T
Haematologica Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells. 103(9):1472-1483 Wu D, Wang W, Chen W, Lian F, Lang L, Huang Y, Xu Y, Zhang N, Chen Y, Liu M, Nussinov R, Cheng F, Lu W, Huang J
Haematologica Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. 103(9):1484-1492 van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, Leverger G, Stary J, De Bont ESJM, Chitu DA, Bertrand Y, Brethon B, Strahm B, van der Sluis IM, Kaspers GJL, Reinhardt D, Zwaan CM
Haematologica Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide. 103(9):1493-1501 Ede BC, Asmaro RR, Moppett JP, Diamanti P, Blair A
Haematologica Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. 103(9):1502-1510 Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P
Haematologica Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. 103(9):1511-1517 Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C
Haematologica GFI1 is required for RUNX1/ETO positive acute myeloid leukemia. 103(9):e395-e399 Marneth AE, Botezatu L, Hönes JM, Israël JCL, Schütte J, Vassen L, Lams RF, Bergevoet SM, Groothuis L, Mandoli A, Martens JHA, Huls G, Jansen JH, Dührsen U, Berg T, Möröy T, Wichmann C, Lo MC, Zhang DE, van der Reijden BA, Khandanpour C
Haematologica Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. 103(9):e400-e403 Martínez-Losada C, Serrano-López J, Serrano-López J, Noguera NI, Garza E, Piredda L, Lavorgna S, Consalvo MAI, Ottone T, Alfonso V, Peinado JR, Garcia-Ortiz MV, Morales-Ruiz T, Jérez A, Hurtado AM, Montesinos P, Cervera J, Such E, Ibañez M, Sempere A, Sanz MÁ, Lo-Coco F, Sánchez-García J
Haematologica Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. 103(9):e404-e407 Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O'Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V
Haematologica NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. 103(9):e424-e426 Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML
Haematologica Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure. 103(9):e427-e431 Ding YY, Stern JW, Jubelirer TF, Wertheim GB, Lin F, Chang F, Gu Z, Mullighan CG, Li Y, Harvey RC, Chen IM, Willman CL, Hunger SP, Li MM, Tasian SK
J Clin Oncol CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. 36(26):2684-2692 Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC
J Clin Oncol Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study. 36(26):2726-2735 Yeoh AEJ, Lu Y, Chin WHN, Chiew EKH, Lim EH, Li Z, Kham SKY, Chan YH, Abdullah WA, Lin HP, Chan LL, Lam JCM, Tan PL, Quah TC, Tan AM, Ariffin H
Lancet T-cell large granular lymphocytic leukaemia in the context of rheumatoid arthritis. 392(10152):1071 Hasanov E, Fard EV, Puravath A, Johnston JS, Peerbhai S, Rojas-Hernandez CM
Lancet Haematol Blurring lines between treatment intensity and patient fitness in elderly people with AML. 5(9):e383-e384 Vey N
Lancet Haematol Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. 5(9):e411-e421 Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H
Lancet Oncol Venetoclax in chronic lymphocytic leukaemia: a possible cure? 19(9):1143-1144 Kallam A, Armitage JO
Lancet Oncol Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. 19(9):1215-1228 Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M
Lancet Oncol Intensified treatment for IKZF1-deleted childhood leukaemia. 19(9):e441 Burki TK
Leukemia The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia. 32(9):1984-1993 Furness CL, Mansur MB, Weston VJ, Ermini L, van Delft FW, Jenkinson S, Gale R, Harrison CJ, Pombo-de-Oliveira MS, Sanchez-Martin M, Ferrando AA, Kearns P, Titley I, Ford AM, Potter NE, Greaves M
Leukemia Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. 32(9):2025-2028 Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW
Leukemia Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. 32(9):2028-2031 Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, Seda V, Fojtova M, Fajkus J, Brychtova Y, Doubek M, Pospisilova S, Mayer J, Mraz M
Leukemia Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. 32(9):2046–2049 Ernst T, Busch M, Rinke J, Ernst J, Haferlach C, Beck JF, Hochhaus A, Gruhn B
Leukemia Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. 32(9):2049-2054 Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, Kovacsovics TJ, Marth GT, O'Hare T, Deininger MW
Leukemia Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia. 32(9):2058-2062 Lundin-Ström KB, Biloglav A, Lilljebjörn H, Rissler M, Fioretos T, Hansson M, Behrendtz M, Castor A, Olsson L, Johansson B
Leukemia Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts. 32(9):2062-2065 Buffière A, Accogli T, Saint-Paul L, Lucchi G, Uzan B, Ballerini P, Bastie JN, Delva L, Pflumio F, Quéré R
Leukemia Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. 32(9):2066–2069 Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P

Lymphoma

Myeloma

SCT

HSC

Anemia

Bone marrow failure

このキーワードに関連した論文はありません

ITP

このキーワードに関連した論文はありません